Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2009

Open Access 01-12-2009 | Research

Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients

Authors: Michael F Gallagher, Richard J Flavin, Salah A Elbaruni, Jamie K McInerney, Paul C Smyth, Yvonne M Salley, Sebastian F Vencken, Sharon A O'Toole, Alexandros Laios, Mathia YC Lee, Karen Denning, Jinghuan Li, Sinead T Aherne, Kai Q Lao, Cara M Martin, Orla M Sheils, John J O'Leary

Published in: Journal of Ovarian Research | Issue 1/2009

Login to get access

Abstract

Background

Tumours with high proportions of differentiated cells are considered to be of a lower grade to those containing high proportions of undifferentiated cells. This property may be linked to the differentiation properties of stem cell-like populations within malignancies. We aim to identify molecular mechanism associated with the generation of tumours with differing grades from malignant stem cell populations with different differentiation potentials. In this study we assessed microRNA (miRNA) regulation in two populations of malignant Embryonal Carcinoma (EC) stem cell, which differentiate (NTera2) or remain undifferentiated (2102Ep) during tumourigenesis, and compared this to miRNA regulation in ovarian serous carcinoma (OSC) patient samples.

Methods

miRNA expression was assessed in NTera2 and 2102Ep cells in the undifferentiated and differentiated states and compared to that of OSC samples using miRNA qPCR.

Results

Our analysis reveals a substantial overlap between miRNA regulation in 2102Ep cells and OSC samples in terms of miRNA biosynthesis and expression of mature miRNAs, particularly those of the miR-17/92 family and clustering to chromosomes 14 and 19. In the undifferentiated state 2102Ep cells expressed mature miRNAs at up to 15,000 fold increased levels despite decreased expression of miRNA biosynthesis genes Drosha and Dicer. 2102Ep cells avoid differentiation, which we show is associated with consistent levels of expression of miRNA biosynthesis genes and mature miRNAs while expression of miRNAs clustering to chromosomes 14 and 19 is deemphasised. OSC patient samples displayed decreased expression of miRNA biosynthesis genes, decreased expression of mature miRNAs and prominent clustering to chromosome 14 but not 19. This indicates that miRNA biosynthesis and levels of miRNA expression, particularly from chromosome 14, are tightly regulated both in progenitor cells and in tumour samples.

Conclusion

miRNA biosynthesis and expression of mature miRNAs, particularly the miR-17/92 family and those clustering to chromosomes 14 and 19, are highly regulated in both progenitor cells and tumour samples. Strikingly, 2102Ep cells are not simply malfunctioning but respond to differentiation specifically, a mechanism that is highly relevant to OSC samples. Our identification and future manipulation of these miRNAs may facilitate generation of lower grade malignancies from these high-grade cells.
Appendix
Available only for authorised users
Literature
1.
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone M: Identification of pancreatic cancer stem cells. Cancer Res 2007,67(3):1030–1037. 10.1158/0008-5472.CAN-06-2030PubMedCrossRef
2.
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Allies LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. PNAS 2007,104(3):973–978. 10.1073/pnas.0610117104PubMedCentralPubMedCrossRef
3.
Szotek P, Pieretti-Vanmarke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, MacLaughlin DT, Donahoe PK: Ovarian cancer side population defines cells with stem-like characteristics and Mullerian Inhibiting Substance responsiveness. PNAS 2006,103(30):11154–11159. 10.1073/pnas.0603672103PubMedCentralPubMedCrossRef
4.
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ: Prospective identification of prostate cancer stem cells. Cancer Res 2005,65(23):10946–51. 10.1158/0008-5472.CAN-05-2018PubMedCrossRef
5.
Galli R, Binda E, Orfanelli U, Cipelletti E, Gritti A, De Vitis S, Fiocco R, Foroin C, Dimenoc F, Vescovi A: Isolation and characterisation of tumourigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64: 7011–7021. 10.1158/0008-5472.CAN-04-1364PubMedCrossRef
6.
Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT: CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004,117(16):3539–3545. 10.1242/jcs.01222PubMedCrossRef
7.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004, 432: 396–401. 10.1038/nature03128PubMedCrossRef
8.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumourigenic breast cancer cells. PNAS 2003, 100: 3983–3988. 10.1073/pnas.0530291100PubMedCentralPubMedCrossRef
9.
Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI: Cancerous stem cells can arise from paediatric brain tumours. PNAS 2003, 100: 15178–15183. 10.1073/pnas.2036535100PubMedCentralPubMedCrossRef
10.
Kleinsmith LJ, Pierce GB: Multipotentiality of single embryonal carcinoma cells. Cancer Res 1964, 24: 1544–1552.PubMed
11.
Andrews PW, Martin MM, Bahrami AR, Damjaov I, Gokhale P, Draper JS: Embryonic stem (ES) cells and embryonal carcinoma (EC) cells: opposite sides of the same coin. Biochem Soc Trans 2005,33(Pt 6):1526–30.PubMed
12.
Andrews PW: From teratocarcinomas to embryonic stem cells. Phil Trans R Soc Lond, B 2002, 357: 405–417. 10.1098/rstb.2002.1058CrossRef
13.
Andrews PW, Damjanov I, Simon D, Banting GS, Carlin C, Dracopoli NC, Fogh J: Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Lab Invest 1984,50(2):147–162.PubMed
14.
Andrews PW, Fenderson B, Hakomori S: Human embryonal carcinoma cells and their differentiation in culture. Intl J Andrology 1987,10(1):95–104. 10.1111/j.1365-2605.1987.tb00170.xCrossRef
15.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics. CA 2008, 58: 71–96.PubMed
16.
Ferlay JBF, Pisani P, Parkin DM: Cancer incidence, mortality and prevalence worldwide. IARC Press: Lyon, Globocon; 2000.
17.
Scully RE: Classificaion of human ovarian tumours. Evviron Health Persp 1987, 73: 15–24. 10.2307/3430594CrossRef
18.
Berry NB, Bapat SA: Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J Ovarian Res 2008, 1: 8. 10.1186/1757-2215-1-8PubMedCentralPubMedCrossRef
19.
Alvero AB, Chen R, Fu H, Montagna M, Schwarts PE, Rutherford T, Silasi D, Steffenson KD, Waldstrom M, Visintin I, Mor G: Molecular phenotyping of ovarian cancer stem cells unravel the mechanisms for repair and chemoresistance. Cell Cycle 2009,8(1):158–166.PubMedCentralPubMedCrossRef
20.
21.
Tay Y, Zhang J, Thompson AM, Lim B, Rigoutsos I: MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008,455(2716):1124–8. 10.1038/nature07299PubMedCrossRef
22.
Place RF, Li L, Pookot D, Noonan EJ, Dahija R: MicroRNA-373 induces expression of genes with complementary promoter sequences. PNAS 2008,105(5):1608–1613. 10.1073/pnas.0707594105PubMedCentralPubMedCrossRef
23.
24.
Esquela-Kerscher A, Slack FJ: OncomiRs-microRNAs with a role in cancer. Nature Rev Cancer 2006, 6: 259–69. 10.1038/nrc1840CrossRef
25.
Micci F, Weimer J, Haugom L, Skotheim RI, Grunewald R, Abeler VM, Silins I, Lothe RA, Trope CG, Arnold N, Heim S: Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. Genes, Chrom Cancer 2009,48(2):184–93. 10.1002/gcc.20628CrossRef
26.
Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Bützow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. PNAS 2008,105(19):7004–9. 10.1073/pnas.0801615105PubMedCentralPubMedCrossRef
27.
Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T: Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008,132(5):875–86. 10.1016/j.cell.2008.02.019PubMedCentralPubMedCrossRef
28.
Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A: Augmentation of tumour angiogenesis by a Myc-activated microRNA cluster. Nature Genet 2006,38(9):1060–5. 10.1038/ng1855PubMedCentralPubMedCrossRef
29.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM: A microRNA polycistron as a potential human oncogene. Nature 2005, 9: 828–833. 10.1038/nature03552CrossRef
30.
Calin GA, Croce CM: MicroRNA signatures in cancer. Nature Rev Cancer 2006, 6: 857–866. 10.1038/nrc1997CrossRef
31.
Lao K, Xu NL, Yeung V, Chen C, Livak KJ, Straus NA: Multi-plexing RT-PCR for the detection of multiple miRNA species in small samples. Biochem Biophys Res Comm 2006, 343: 85–9. 10.1016/j.bbrc.2006.02.106PubMedCrossRef
32.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ddCt method. Methods 2001, 25: 402–8. 10.1006/meth.2001.1262PubMedCrossRef
33.
34.
Megraw M, Sethupathy P, Corda B, Hatzigeorgiou AG: miRGen: A database for the study of animal microRNA genomic organisation and function. Nucleic Acids Res 2006, 35: D149-D155. 10.1093/nar/gkl904PubMedCentralPubMedCrossRef
35.
Flavin RJ, Smyth PC, Finn SP, Laois A, O'Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne AT, Aziz NA, Alhadi A, Sheppard BL, Loda M, Martin C, Sheils OM, O'Leary JJ: Altered eIF6 and dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Mod Path 2008, 21: 676–684. 10.1038/modpathol.2008.33CrossRef
36.
Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, Zhang Y, Wood W, Becker KG, Morin PJ: MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE 2008, 3: e2436. 10.1371/journal.pone.0002436PubMedCentralPubMedCrossRef
37.
Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Lui GC, Aider H, Calin GA, Menard S, Croce CM: MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67: 8699–707. 10.1158/0008-5472.CAN-07-1936PubMedCrossRef
38.
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008,14(9):2690–5. 10.1158/1078-0432.CCR-07-1731PubMedCrossRef
39.
Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumour-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynae Oncol 2008,110(1):13–21. 10.1016/j.ygyno.2008.04.033CrossRef
40.
Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Bützow R, Croce CM, Coukos G, Zhang L: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008,68(24):10307–14. 10.1158/0008-5472.CAN-08-1954PubMedCentralPubMedCrossRef
41.
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK: Dicer, Drosha and outcomes in patients with ovarian cancer. N Engl J Med 2008,359(25):2641–50. 10.1056/NEJMoa0803785PubMedCentralPubMedCrossRef
42.
Zhu R, Ji Y, Xiao L, Matin A: Testicular germ cell tumour susceptibility genes from the consomic 129. MOLF-Chr19 mouse strain. Mamm Gene 2007, 18: 584–95. 10.1007/s00335-007-9036-2CrossRef
43.
Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce CM: MicroRNA fingerprints during megakaryocytopoiesis. PNAS 2006,103(13):5078–83. 10.1073/pnas.0600587103PubMedCentralPubMedCrossRef
44.
Lin EA, Kong L, Bai XH, Luan Y, Liu CJ: Mir-199a, a bone morphogenic protein 2-response microRNAs, regulates chondrogenesis via direct targeting to Smad1. J Biol Chem 2009,284(17):11326–35. 10.1074/jbc.M807709200PubMedCentralPubMedCrossRef
45.
Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ: MyoD inhibits Fstl1 and Utrn expression by inducing expression of miR-206. J Cell Biol 2009,175(1):77–85. 10.1083/jcb.200603039CrossRef
46.
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnston TM, Morrison SJ: Efficient tumour formation by single human melanoma cells. Nature 2008,456(7222):593–8. 10.1038/nature07567PubMedCentralPubMedCrossRef
47.
Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P, Lee CG: Profilin miRNA expression in hepatocellular carcinoma reveals microRNAs-244 up-regulation and apoptosis inhibitor-5 as a microRNAs-224-specific target. J Biol Chem 2008,283(19):13205–15. 10.1074/jbc.M707629200PubMedCrossRef
48.
49.
50.
Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P: The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009,69(8):3356–63. 10.1158/0008-5472.CAN-08-4112PubMedCentralPubMedCrossRef
51.
Ju X, Li D, Shi Q, Hou H, Sun N, Shen B: Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009,26(1):1–10. 10.1080/08880010802378338CrossRef
52.
Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuuring E, Kluin P, Berg A: Specific expression of miR-17–5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Path 2009,22(4):547–55. 10.1038/modpathol.2009.10CrossRef
53.
Navarro A, Marrades RM, Viñolas N, Quera A, Agustí C, Huerta A, Ramirez J, Torres A, Monzo M: MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 2009,76(3):162–9. 10.1159/000201569PubMedCrossRef
54.
Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B, Meng X, Ma X, Luo M, Shao K, Li N, Qiu B, Mitchelson K, Cheng J, He J: Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008,68(1):26–33. 10.1158/0008-5472.CAN-06-4418PubMedCrossRef
55.
Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, Goggins MG, Mendell JT, Maitra A: Epigenetic Silencing of MicroRNA miR-107 Regulates Cyclin-Dependent Kinase 6 Expression in Pancreatic Cancer. Pancreatology 2009,9(3):293–301. 10.1159/000186051PubMedCentralPubMedCrossRef
56.
Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K, Mori M: Over- and under-expressed microRNAs in human colorectal cancer. Intl J Oncol 2009,34(4):1069–75.
57.
Mraz M, Pospisilova S, Malinova K, Slapak I, Mayer J: MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma 2009,50(3):506–9. 10.1080/10428190902763517PubMedCrossRef
58.
Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J: MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009,16(3):206–16.PubMed
59.
Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ: MicroRNA signatures predict estrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009, 11: R27. 10.1186/bcr2257PubMedCentralPubMedCrossRef
60.
Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK, Kim VN: Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 2009,37(5):1672–81. 10.1093/nar/gkp002PubMedCentralPubMedCrossRef
61.
Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008,111(3):478–86. 10.1016/j.ygyno.2008.08.017PubMedCrossRef
62.
Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M, Ju J: Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights 2006, 2: 113–121.PubMed
63.
Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, Hahn SA: MicroRNA expression alterations are linked to tumourigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007,26(30):4442–52. 10.1038/sj.onc.1210228PubMedCrossRef
64.
Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, DiRenzo J, Korc M, Cole CN, Bak M, Kauppinen S, Dmitrovsky E: Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res 2009,15(4):1177–83. 10.1158/1078-0432.CCR-08-1355PubMedCentralPubMedCrossRef
65.
Siva AC, Nelson LJ, Fleischer CL, Majlessi M, Becker MM, Vessella RL, Reynolds MA: Molecular assays for the detection of microRNAs in prostate cancer. Molec Cancer 2009, 8: 17. 10.1186/1476-4598-8-17CrossRef
66.
Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI: Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 2008,14(9):2588–92. 10.1158/1078-0432.CCR-07-0666PubMedCrossRef
67.
Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, Burny A, Sculier JP: Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Resp J 2009,33(2):352–9. 10.1183/09031936.00084108CrossRef
68.
Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S: CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Gene Chrom Cancer 2009,48(7):615–23. 10.1002/gcc.20669CrossRef
69.
Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ: Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009,284(9):5731–41. 10.1074/jbc.M804280200PubMedCrossRef
70.
Adams BD, Cowee DM, White BA: The Role of miR-206 in The Epidermal Growth Factor (EGF) Induced Repression of Estrogen Receptor-alpha (ER{alpha}) Signaling and a Luminal Phenotype in MCF-7 Breast Cancer Cells. Molec Endocrinol 2009,23(8):1215–30. 10.1210/me.2009-0062CrossRef
71.
O'Hara AJ, Chugh P, Wang L, Netto EM, Luz E, Harrington WJ, Dezube BJ, Damania B, Dittmer DP: Pre-micro RNA signatures delineate stages of endothelial cell transformation in kaposi sarcoma. PLoS Pathogens 2009,5(4):e1000389. 10.1371/journal.ppat.1000389PubMedCentralPubMedCrossRef
72.
Wu W, Lin Z, Zhuang Z, Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 2009,18(1):50–55. 10.1097/CEJ.0b013e328305a07aPubMedCrossRef
73.
Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, Osada H, Nagino M, Takahashi T: Detailed characterization of a homozygously deleted region corresponding to a candidate tumour suppressor locus at 21q11–21 in human lung cancer. Gene Chrom Cancer 2008,47(9):810–8. 10.1002/gcc.20582CrossRef
74.
Ronchetti D, Lionetti M, Mosca L, Agnelli L, Andronache A, Fabris S, Deliliers GL, Neri A: An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genom 2008, 1: 37. 10.1186/1755-8794-1-37CrossRef
75.
Tan Y, Zhang B, Wu T, Skogerbø G, Zhu X, Guo X, He S, Chen R: Transcriptional inhibition of Hoxd4 expression by miRNA-10a in human breast cancer cells. BMC Molec Biol 2009, 10: 12. 10.1186/1471-2199-10-12CrossRef
76.
Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, Pérez-Roger I, García-Foncillas J, Torres A, Heiniger A, Calasanz MJ, Fortes P, Román-Gómez J, Prósper F: Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Molec Cancer Res 2008,6(12):1830–40. 10.1158/1541-7786.MCR-08-0167CrossRef
77.
Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008,27(12):1788–93. 10.1038/sj.onc.1210809PubMedCrossRef
78.
Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T: Suppression of non-small cell lung tumour development by the let-7 microRNA family. PNAS 2008,105(10):3903–8. 10.1073/pnas.0712321105PubMedCentralPubMedCrossRef
79.
Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J: Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genom Proteom 2006,3(5):317–324.
80.
Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Vecchio LD, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M: MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS ONE 2009,4(3):e4998. 10.1371/journal.pone.0004998PubMedCentralPubMedCrossRef
81.
Lum AM, Wang BB, Li L, Channa N, Bartha G, Wabl M: Retroviral activation of the mir-106a microRNA cistron in T lymphoma. Retrovirol 2007, 4: 5. 10.1186/1742-4690-4-5CrossRef
82.
Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, Ogawa R, Harata K, Fujii Y: microRNA expression profile in undifferentiated gastric cancer. Intl J Oncol 2009,34(2):537–42.
83.
Chen Y, Stallings RL: Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007,67(3):976–83. 10.1158/0008-5472.CAN-06-3667PubMedCrossRef
84.
Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N, Rechavi G, Givol D: MIR-451 and Imatinib mesylate inhibit tumour growth of Glioblastoma stem cells. Biochem Biophys Res Comm 2008,376(1):86–90. 10.1016/j.bbrc.2008.08.107PubMedCrossRef
85.
Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ, Schmittgen TD: Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumours. RNA 2008,14(1):35–42. 10.1261/rna.804508PubMedCentralPubMedCrossRef
86.
Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumour stem cells. BMC Med 2008, 6: 14. 10.1186/1741-7015-6-14PubMedCentralPubMedCrossRef
87.
Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA: MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 2008,68(5):1362–8. 10.1158/0008-5472.CAN-07-2912PubMedCrossRef
88.
Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, Croce CM: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumours are associated with distinctive pathologic features and clinical behavior. J of Clin Oncol 2006,24(29):4677–84. 10.1200/JCO.2005.05.5194CrossRef
89.
Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumourous tissues. J Gastroenterol Hepatol 2009,24(4):652–7. 10.1111/j.1440-1746.2008.05666.xPubMedCrossRef
90.
Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008,14(11):2348–60. 10.1261/rna.1034808PubMedCentralPubMedCrossRef
91.
Pizzimenti S, Ferracin M, Sabbioni S, Toaldo C, Pettazzoni P, Dianzani MU, Negrini M, Barrera G: MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation. Free Radic Biol Med 2008,46(2):282–8. 10.1016/j.freeradbiomed.2008.10.035PubMedCrossRef
92.
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM: MicroRNA-195 suppresses tumourigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009,50(1):113–21. 10.1002/hep.22919PubMedCrossRef
93.
Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Intl J Cancer 2009,125(2):345–52. 10.1002/ijc.24390CrossRef
94.
Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynaecol Oncol 2009,114(3):457–64. 10.1016/j.ygyno.2009.05.022CrossRef
95.
Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A: MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Path 2009, 10: 1002.
96.
Mees ST, Mardin WA, Wendel C, Baeumer N, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J: EP300 - a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Intl J Cancer 2009.,9999(999A): NA
97.
Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, Si J: Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 2009,44(6):556–61. 10.1007/s00535-009-0037-7PubMedCrossRef
98.
Cho WC, Chow AS, Au JS: Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J of Cancer 2009,45(12):2197–206. 10.1016/j.ejca.2009.04.039CrossRef
99.
Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE: MicroRNA expression profiling of thyroid tumours: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008,3(5):1600–8. 10.1210/jc.2007-2696CrossRef
100.
Lee KH, Goan YG, Hsiao M, Lee CH, Jian SH, Lin JT, Chen YL, Lu PJ: MicroRNA-373(miR-373) post-transcriptionally regulates large tumour suppressor, homolog 2(LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res 2009,315(15):2529–38. 10.1016/j.yexcr.2009.06.001PubMedCrossRef
Metadata
Title
Regulation of microRNA biosynthesis and expression in 2102Ep embryonal carcinoma stem cells is mirrored in ovarian serous adenocarcinoma patients
Authors
Michael F Gallagher
Richard J Flavin
Salah A Elbaruni
Jamie K McInerney
Paul C Smyth
Yvonne M Salley
Sebastian F Vencken
Sharon A O'Toole
Alexandros Laios
Mathia YC Lee
Karen Denning
Jinghuan Li
Sinead T Aherne
Kai Q Lao
Cara M Martin
Orla M Sheils
John J O'Leary
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2009
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/1757-2215-2-19

Other articles of this Issue 1/2009

Journal of Ovarian Research 1/2009 Go to the issue

Research

Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies

Review

Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature

Review

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Research

Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysis

Review

Oocyte-granulosa-theca cell interactions during preantral follicular development

Review

Enhancing the efficacy of cisplatin in ovarian cancer treatment – could arsenic have a role